Answers are grounded in this paper and cite their sources.
Evaluates antihypertensive effects of red tilapia viscera in hypertensive rats, suggesting potential for drug development.
Introduction/Objective: This study aimed to evaluate the in vitro and in vivo antihypertensive effects of red tilapia (Oreochromis spp.) viscera hydrolysate and its fractions. Methods: The viscera were hydrolyzed by Alcalase® 2.4L, and their fractions were separated in a ceramic tubular membranes system with an MWCO of 3 kDa, obtaining >3 kDa and < 3 kDa fractions. Both hydrolysate and fractions were evaluated for vasodilatory effect in rat aorta rings and in an acute test involving normotensive rats. In addition, the chronic antihypertensive effect of the fraction < 3 kDa was evaluated in hypertensive rats for 35 days, using doses of 75 and 150 mg/kg, respectively. Results: The hydrolysate induced vasodilation in rat aorta rings through an endotheliumdependent nitric oxide (NO) pathway. In the acute in vivo test, hydrolysates and fractions significantly decreased rat systolic pressure, with the < 3 kDa fraction showing the most potent effect. Discussion: Meanwhile, in the chronic antihypertensive study with rats, a blood pressure drop was observed over time, reducing systolic blood pressure to 122.7 mmHg on day 29 of the study, using the fraction < 3 kDa. Conclusion: The results suggested the hydrolysate and fractions under study contain bioactive peptides with potential for the development of antihypertensive drugs.
No takes yet. Share an insight, caveat, or question.
Arias et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: